Insights Into Breast Cancer 2020 Southeast
Community physician perspectives on current treatment practices regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer, and attitudes toward recently introduced and upcoming agents
Southeast – July 8, 2020
Faculty Chair
Adam Brufsky, MD, PhD
UPMC Hillman Cancer Center, Pittsburgh, PA, USA
REPORT SNAPSHOT
- A roundtable discussion, moderated by an Axess Oncology Network physician, focusing on treatment of metastatic breast cancer was held via a virtual platform on July 8, 2020
- Disease state and data presentations were developed in conjunction with Adam Brufsky, MD, PhD, a medical expert from the University of Pittsburgh
- Insights on the following therapies were obtained:
- HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, HDAC inhibitors, chemotherapies
- HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, tucatinib, neratinib, AIs, mTOR inhibitors, chemotherapies
- TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan, GPNMB), immunotherapy, chemotherapies
- Data collection was accomplished through use of audience response system questioning and moderated discussion
GEOGRAPHIC REPRESENTATION
- The group of advisors comprised community oncologists from the southeast region of the United States
- Attendees of the roundtable represented community oncologists from Florida, Georgia, South Carolina, and Virginia
